ATA13752002A - Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen - Google Patents

Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen

Info

Publication number
ATA13752002A
ATA13752002A AT0137502A AT13752002A ATA13752002A AT A13752002 A ATA13752002 A AT A13752002A AT 0137502 A AT0137502 A AT 0137502A AT 13752002 A AT13752002 A AT 13752002A AT A13752002 A ATA13752002 A AT A13752002A
Authority
AT
Austria
Prior art keywords
immunotherapeuticum
cellular
releasing
producing
dendritic cells
Prior art date
Application number
AT0137502A
Other languages
English (en)
Other versions
AT412145B (de
Inventor
Thomas Dr Felzmann
Original Assignee
Forsch Krebskranke Kinder
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to AT0137502A priority Critical patent/AT412145B/de
Application filed by Forsch Krebskranke Kinder filed Critical Forsch Krebskranke Kinder
Priority to US10/527,679 priority patent/US7867488B2/en
Priority to PCT/EP2003/009591 priority patent/WO2004024900A1/en
Priority to CA2494216A priority patent/CA2494216C/en
Priority to PT03794972T priority patent/PT1537203E/pt
Priority to DK03794972.4T priority patent/DK1537203T3/da
Priority to JP2004535211A priority patent/JP2005538167A/ja
Priority to SI200332142T priority patent/SI1537203T1/sl
Priority to EP03794972A priority patent/EP1537203B1/de
Priority to ES03794972T priority patent/ES2381870T3/es
Priority to AU2003260473A priority patent/AU2003260473B2/en
Priority to AT03794972T priority patent/ATE544847T1/de
Publication of ATA13752002A publication Critical patent/ATA13752002A/de
Application granted granted Critical
Publication of AT412145B publication Critical patent/AT412145B/de
Priority to CY20121100427T priority patent/CY1112740T1/el

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0639—Dendritic cells, e.g. Langherhans cells in the epidermis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/19—Dendritic cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/24—Antigen-presenting cells [APC]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/34—Antigenic peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/428—Undefined tumor antigens, e.g. tumor lysate or antigens targeted by cells isolated from tumor
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/31—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterized by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/38—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/48—Blood cells, e.g. leukemia or lymphoma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/53—Liver
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2239/00—Indexing codes associated with cellular immunotherapy of group A61K40/00
    • A61K2239/46—Indexing codes associated with cellular immunotherapy of group A61K40/00 characterised by the cancer treated
    • A61K2239/56—Kidney
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/05—Adjuvants
    • C12N2501/052—Lipopolysaccharides [LPS]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/22—Colony stimulating factors (G-CSF, GM-CSF)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/24—Interferons [IFN]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AT0137502A 2002-09-13 2002-09-13 Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen AT412145B (de)

Priority Applications (13)

Application Number Priority Date Filing Date Title
AT0137502A AT412145B (de) 2002-09-13 2002-09-13 Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
EP03794972A EP1537203B1 (de) 2002-09-13 2003-08-29 Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren
CA2494216A CA2494216C (en) 2002-09-13 2003-08-29 Use of dendritic cells (dcs) expressing interleukin 12 (il-12)
PT03794972T PT1537203E (pt) 2002-09-13 2003-08-29 Utilização de células dendríticas (dcs) expressando interleucina 12 (il-12)
DK03794972.4T DK1537203T3 (da) 2002-09-13 2003-08-29 ANVENDELSE AF DENDRITISKE CELLER (DC'er) DER UDTRYKKER INTERLEUKIN 12 (IL-12)
JP2004535211A JP2005538167A (ja) 2002-09-13 2003-08-29 インターロイキン１２（ｉｌ−１２）を発現する樹状細胞（ｄｃ）の使用
US10/527,679 US7867488B2 (en) 2002-09-13 2003-08-29 Use of dendritic cells (DCs) expressing interleukin 12 (IL-12)
PCT/EP2003/009591 WO2004024900A1 (en) 2002-09-13 2003-08-29 USE OF DENDRITIC CELLS (DCs) EXPRESSING INTERLEUKIN 12 (IL-12)
ES03794972T ES2381870T3 (es) 2002-09-13 2003-08-29 Utilización de células dendríticas (CD) que expresan interleucina 12 (IL-12)
AU2003260473A AU2003260473B2 (en) 2002-09-13 2003-08-29 Use of dendritic cells (DCs) expressing interleukin 12 (IL-12)
AT03794972T ATE544847T1 (de) 2002-09-13 2003-08-29 Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren
SI200332142T SI1537203T1 (sl) 2002-09-13 2003-08-29 Uporaba dendritičnih celic (DC), ki eksprimirajo interlevkin 12 (IL-12)
CY20121100427T CY1112740T1 (el) 2002-09-13 2012-05-08 ΧΡΗΣΗ ΔΕΝΔΡΙΤΙΚΩΝ ΚΥΤΤΑΡΩΝ (DCs) ΕΚΦΡΑΖΟΝΤΑΣ ΙΝΤΕΡΛΕΥΚΙΝΗ 12 (IL-12)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
AT0137502A AT412145B (de) 2002-09-13 2002-09-13 Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen

Publications (2)

Publication Number Publication Date
ATA13752002A true ATA13752002A (de) 2004-03-15
AT412145B AT412145B (de) 2004-10-25

Family

ID=31892564

Family Applications (2)

Application Number Title Priority Date Filing Date
AT0137502A AT412145B (de) 2002-09-13 2002-09-13 Verfahren zur herstellung eines zellulären immuntherapeutikums auf basis von il-12-freisetzenden dendritischen zellen
AT03794972T ATE544847T1 (de) 2002-09-13 2003-08-29 Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren

Family Applications After (1)

Application Number Title Priority Date Filing Date
AT03794972T ATE544847T1 (de) 2002-09-13 2003-08-29 Verwendung von dendritischen zellen, die interleukin 12 (il-12) exprimieren

Country Status (12)

Country Link
US (1) US7867488B2 (de)
EP (1) EP1537203B1 (de)
JP (1) JP2005538167A (de)
AT (2) AT412145B (de)
AU (1) AU2003260473B2 (de)
CA (1) CA2494216C (de)
CY (1) CY1112740T1 (de)
DK (1) DK1537203T3 (de)
ES (1) ES2381870T3 (de)
PT (1) PT1537203E (de)
SI (1) SI1537203T1 (de)
WO (1) WO2004024900A1 (de)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1757680B1 (de) * 2004-05-11 2009-09-16 Shukokai Incorporated Methoden zur Kultivierung von Antigen presentierenden Immunzellen
AU2013206016B2 (en) * 2005-12-08 2016-08-11 Northwest Biotherapeutics, Inc. Compositions and methods for inducing the activation of immature monocytic dendritic cells
EP1957634A4 (de) * 2005-12-08 2010-01-27 Northwest Biotherapeutics Inc Zusammensetzungen und verfahren zur induzierung der aktivierung unreifer monozytischer dendritenzellen
EP2072617A1 (de) * 2007-12-12 2009-06-24 Trimed Biotech GmbH Verfahren zur Herstellung dendritischer Zellen
JP2013522309A (ja) * 2010-03-15 2013-06-13 ザ トラスティーズ オブ ザ ユニバーシティ オブ ペンシルバニア 活性化した成熟樹状細胞を調製し保存するシステムおよび方法
RU2678083C2 (ru) * 2012-06-27 2019-01-23 Кенитиро Хасуми Терапия и способ внутриопухолевого введения цитотоксического т-лимфоцита и/или nkt-клетки с антителом против tnf и/или антителом против il-10
US10238723B2 (en) 2013-03-14 2019-03-26 Icahn School Of Medicine At Mount Sinai Autologous tumor lysate-loaded dendritic cell vaccine for treatment of liver cancer
EP2787005A1 (de) 2013-04-02 2014-10-08 Activartis Biotech GmbH Gezielte Krebs-Immuntherapie
KR102091748B1 (ko) * 2018-05-04 2020-03-20 차의과학대학교 산학협력단 수지상세포의 이동능을 증가시키는 방법 및 이의 용도
US12605349B2 (en) 2024-09-05 2026-04-21 Orbus Therapeutics, Inc. Methods of treating grade 3 astrocytoma

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6479254B2 (en) * 1996-03-22 2002-11-12 Human Genome Sciences, Inc. Apoptosis inducing molecule II
FR2796961B1 (fr) * 1999-07-29 2003-05-02 Chu Montpellier Procede d'obtention de cellules dentritiques, les cellules dentritiques ainsi obtenues et leurs utilisations a des fins cliniques
WO2001039600A1 (en) * 1999-12-03 2001-06-07 University Of Massachusetts Use of hsp27 as an anti-inflammatory agent
AU2000227285A1 (en) * 2000-01-14 2001-07-24 The Government Of The United States Of America As Represented By The Secretary, Department Of Health And Human Services Methods of regulating il-12 production by administering ccr5 agonists and antagonists
US20030003579A1 (en) * 2000-10-24 2003-01-02 Norimitsu Kadowaki Dendritic cells; methods
BRPI0212545B8 (pt) * 2001-09-06 2021-05-25 Northwest Biotherapeutics Inc método ex vivo ou in vitro para produzir uma população de célula dendrítica madura e método para produzir células t

Also Published As

Publication number Publication date
PT1537203E (pt) 2012-05-21
EP1537203B1 (de) 2012-02-08
EP1537203A1 (de) 2005-06-08
ES2381870T3 (es) 2012-06-01
US20060177420A1 (en) 2006-08-10
CA2494216A1 (en) 2004-03-25
US7867488B2 (en) 2011-01-11
CY1112740T1 (el) 2016-02-10
JP2005538167A (ja) 2005-12-15
SI1537203T1 (sl) 2012-06-29
AT412145B (de) 2004-10-25
AU2003260473A1 (en) 2004-04-30
AU2003260473B2 (en) 2008-08-07
WO2004024900A1 (en) 2004-03-25
CA2494216C (en) 2013-07-09
DK1537203T3 (da) 2012-05-14
ATE544847T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
ATE468314T1 (de) Verfahren zur herstellung von ameisensäure
ATE408609T1 (de) Verfahren zur herstellung von n-phenylpyrazol-1- carboxamiden
ATE515500T1 (de) Verfahren zur herstellung von telmisartan
ATE479409T1 (de) Verfahren zur herstellung von saugkernen
DE602005026478D1 (de) Verfahren zur Herstellung von dünnwandigen Isogittergehäusen
ATE414077T1 (de) Verfahren zur herstellung von 1-ä(benzimidazol-1- yl)chinolin-8-ylüpiperidin-4-ylaminderivaten
ATE316434T1 (de) Verfahren zur herstellung eines formteiles
DE602005023477D1 (de) Batteriemodul, batteriepack und verfahren zur herstellung eines batteriemoduls
ATA11912002A (de) Verfahren zur herstellung von fälschungssicheren identifikationsmerkmalen
ATE414058T1 (de) Verfahren zur herstellung eines sulfinyl- acetamids
ATE399157T1 (de) Verfahren zur herstellung von telmisartan
DE602004019853D1 (de) Verfahren zur Herstellung einer Alkalibatterie
EP1811594A4 (de) Verfahren zur herstellung eines elektrodenkatalysators
DE60327168D1 (de) Verfahren zur herstellung eines eingebetteten widerstands
DE50308650D1 (de) Verfahren zur herstellung von cellulosecarbamatformkörpern
EP1778419A4 (de) Verfahren zur herstellung von extrusionswerkzeugen
DE60317715D1 (de) Verfahren zur herstellung eines sektionaltorpaneels
DE60329907D1 (de) Verfahren zur herstellung von wasserlöslichem carboxyliertem polymer
ATE553103T1 (de) Verfahren zur herstellung von (s)-pantoprazol
DE10332093A8 (de) Verfahren zur Herstellung einer elektrochemischen Zelle sowie die elektrochemische Zelle
DE602004000126D1 (de) Verfahren zur Herstellung von selbststanzenden Muttern
DE50308653D1 (de) Verfahren zur herstellung einer nrom-speicherzellenanordnung
DE50303611D1 (de) Verfahren zur herstellung von polyisobuten
ATE402138T1 (de) Verfahren zur herstellung von 2- aminoindanderivaten
DE60336173D1 (de) Verfahren zur herstellung von vanadylpyrophosphat-katalysatoren

Legal Events

Date Code Title Description
MM01 Lapse because of not paying annual fees

Effective date: 20130315